BR0307444A - Derivados piridino amiudo como inibidores de moniamina oxidase (mao-b) - Google Patents
Derivados piridino amiudo como inibidores de moniamina oxidase (mao-b)Info
- Publication number
- BR0307444A BR0307444A BR0307444-7A BR0307444A BR0307444A BR 0307444 A BR0307444 A BR 0307444A BR 0307444 A BR0307444 A BR 0307444A BR 0307444 A BR0307444 A BR 0307444A
- Authority
- BR
- Brazil
- Prior art keywords
- mao
- oxidase inhibitors
- moniamine
- pyridine derivatives
- pyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"DERIVADOS PIRIDINO AMIDO COMO INIBIDORES DE MONOAMINA OXIDASE (MAO-B)". Esta invenção refere-se a derivados de piridino amido da fórmula genérica onde um de X ou Y é -N= e o outro é -CR7= , e R^ 1^ a R^ 7^ são como definidos no relatório descritivo. A invenção ainda refere-se a medicamentos contendo estes compostos, um processo para sua preparação assim como seu uso para preparação de medicamentos para o tratamento ou prevenção de doenças nas quais inibidores de MAO-B podem ser benéficos. Estas doenças incluem doenças neurológicas como Alzheimer, demência, mal de Parkinson e depressão.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02001969 | 2002-02-04 | ||
PCT/EP2003/000769 WO2003066596A1 (en) | 2002-02-04 | 2003-01-27 | Pyridineamido derivatives as inhibitors of monoamine oxidase (mao-b) |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0307444A true BR0307444A (pt) | 2004-12-28 |
Family
ID=27675593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0307444-7A BR0307444A (pt) | 2002-02-04 | 2003-01-27 | Derivados piridino amiudo como inibidores de moniamina oxidase (mao-b) |
Country Status (13)
Country | Link |
---|---|
US (1) | US6667327B2 (pt) |
EP (1) | EP1474394A1 (pt) |
JP (1) | JP4217159B2 (pt) |
KR (1) | KR100621297B1 (pt) |
CN (1) | CN1261414C (pt) |
AR (1) | AR038342A1 (pt) |
AU (1) | AU2003205677B2 (pt) |
BR (1) | BR0307444A (pt) |
CA (1) | CA2473459A1 (pt) |
MX (1) | MXPA04007501A (pt) |
PL (1) | PL372226A1 (pt) |
RU (1) | RU2309950C2 (pt) |
WO (1) | WO2003066596A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1680127B1 (en) * | 2003-10-23 | 2008-10-15 | F. Hoffmann-La Roche Ag | Benzazepine derivatives as mao-b inhibitors |
EP1855655A2 (en) | 2005-02-25 | 2007-11-21 | F. Hoffmann-Roche AG | Tablets with improved drug substance dispersibility |
WO2006138475A2 (en) * | 2005-06-16 | 2006-12-28 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
BR112012006330A2 (pt) * | 2009-09-21 | 2017-07-04 | Janssen Cilag S A | análogos de o-benzil nicotinamida como moduladores alostéricos positivos de mglur5 |
IT1404729B1 (it) * | 2011-01-27 | 2013-11-29 | Univ Pisa | Inibitori altamente selettivi dell'attivita' di adams |
KR101746060B1 (ko) | 2015-09-18 | 2017-06-12 | 한국과학기술연구원 | 항비만 치료용 가역적 마오비 저해제 |
CN105601563B (zh) * | 2015-12-17 | 2018-05-08 | 浙江工业大学 | 6-氯-n-(4-(6-氯烟酰胺)苄基)烟酰胺及其制备和应用 |
CN108912029B (zh) * | 2017-08-25 | 2021-10-01 | 广东东阳光药业有限公司 | 含氮杂环酰胺衍生物及其用途 |
CN107903289B (zh) * | 2017-11-08 | 2020-07-31 | 中国科学院烟台海岸带研究所 | 一种基于花菁的有机化合物及其应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1261335A (en) | 1984-08-29 | 1989-09-26 | Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee | Ethylenediamine monoamide derivatives |
HUT43322A (en) * | 1985-09-24 | 1987-10-28 | Schering Ag | Compositions with herbicidal effect comprising imidazolinyl derivatives as active substance and process for preparing the active substances |
JPH02142774A (ja) | 1988-11-25 | 1990-05-31 | Mitsui Toatsu Chem Inc | 2−(4−置換フェニル)イミダゾリノン類、その製造法、およびそれらを有効成分として含有する除草剤 |
IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
CA2090857A1 (en) | 1990-09-17 | 1992-03-18 | David A. Clark | 5-trifluoroacylamino-2-aryloxazoles 2-aryl-5-trifluoroacylaminooxazoles |
GB9306886D0 (en) | 1993-04-01 | 1993-05-26 | Erba Carlo Spa | Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation |
GB9515412D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
WO1999014334A1 (en) | 1997-09-19 | 1999-03-25 | American Cyanamid Company | Peptides derived from the attachment (g) protein of respiratory syncytial virus |
EP2201944B1 (en) | 1997-11-21 | 2012-05-23 | Purdue Neuroscience Company | Use of substituted 2-aminoacetamides for treating, preventing or ameliorating manic depression |
GB9727521D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Substituted 2-benzylamino-2-phenyl-acetamide compounds |
EP1073623B1 (en) | 1998-04-20 | 2007-04-11 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted amino acids as erythropoietin mimetics |
US6294694B1 (en) | 1999-06-04 | 2001-09-25 | Wisconsin Alumni Research Foundation | Matrix metalloproteinase inhibitors and method of using same |
DE19952146A1 (de) | 1999-10-29 | 2001-06-07 | Boehringer Ingelheim Pharma | Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US6306911B1 (en) | 2000-02-07 | 2001-10-23 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted amino acids as neutral sphingomyelinase inhibitors |
-
2003
- 2003-01-14 US US10/341,672 patent/US6667327B2/en not_active Expired - Fee Related
- 2003-01-27 JP JP2003565970A patent/JP4217159B2/ja not_active Expired - Fee Related
- 2003-01-27 KR KR1020047011975A patent/KR100621297B1/ko not_active IP Right Cessation
- 2003-01-27 MX MXPA04007501A patent/MXPA04007501A/es active IP Right Grant
- 2003-01-27 EP EP03702531A patent/EP1474394A1/en not_active Withdrawn
- 2003-01-27 CN CNB038032651A patent/CN1261414C/zh not_active Expired - Fee Related
- 2003-01-27 CA CA002473459A patent/CA2473459A1/en not_active Abandoned
- 2003-01-27 AU AU2003205677A patent/AU2003205677B2/en not_active Ceased
- 2003-01-27 RU RU2004126861/04A patent/RU2309950C2/ru not_active IP Right Cessation
- 2003-01-27 WO PCT/EP2003/000769 patent/WO2003066596A1/en active Application Filing
- 2003-01-27 PL PL03372226A patent/PL372226A1/xx not_active Application Discontinuation
- 2003-01-27 BR BR0307444-7A patent/BR0307444A/pt not_active IP Right Cessation
- 2003-02-03 AR ARP030100319A patent/AR038342A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20030158235A1 (en) | 2003-08-21 |
AR038342A1 (es) | 2005-01-12 |
AU2003205677A1 (en) | 2003-09-02 |
CN1261414C (zh) | 2006-06-28 |
JP2005528339A (ja) | 2005-09-22 |
KR20040082407A (ko) | 2004-09-24 |
RU2004126861A (ru) | 2005-05-27 |
MXPA04007501A (es) | 2004-11-10 |
PL372226A1 (en) | 2005-07-11 |
US6667327B2 (en) | 2003-12-23 |
AU2003205677B2 (en) | 2008-04-24 |
WO2003066596A1 (en) | 2003-08-14 |
KR100621297B1 (ko) | 2006-09-13 |
EP1474394A1 (en) | 2004-11-10 |
JP4217159B2 (ja) | 2009-01-28 |
RU2309950C2 (ru) | 2007-11-10 |
CA2473459A1 (en) | 2003-08-14 |
CN1628102A (zh) | 2005-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607927A2 (pt) | derivados de pirazol-pirimidina | |
BR0309167A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação | |
ATE388951T1 (de) | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes | |
BRPI0517458A (pt) | derivados da xantina com atividade para o receptor hm74a | |
BRPI0517559A (pt) | composto, processo para a sua preparação, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptb-1b e utilização dos compostos | |
BRPI0509504A (pt) | compostos de tiadiazol-amina para o tratamento de distúrbios neurodegenerativos | |
BRPI0615145A2 (pt) | derivados de xantina como agonistas hm74a seletivos | |
BR0314299A (pt) | Derivados de pirrolidona como inibidores de mao-b | |
BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
ATE440087T1 (de) | 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen | |
BRPI0407504A (pt) | heterociclos n-arila substituìdo, processo para sua preparação e uso dos mesmos como medicamentos | |
BR0314611A (pt) | Compostos de tiazol para o tratamento de distúrbios neurodegenerativos | |
ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
PL1789398T3 (pl) | Pochodne 2-amino-chinazoliny użyteczne jako inhibitory ß-sekretazy (BACE) | |
WO2005090296A3 (en) | N-substituted benzene sulfonamides | |
BR0307291A (pt) | Composto; processo para a preparação de um composto; composição farmacêutica; uso de um composto; método para o tratamento e profilaxia de distúrbios diversos e de obesidade em um humano | |
BRPI0413245A (pt) | compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos | |
BRPI0411294A (pt) | derivados de amino-propanol | |
BRPI0713443A2 (pt) | Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos | |
BRPI0509515A (pt) | composto, formulação farmacêutica, uso de um composto método para tratamento de doenças, e, processo para a preparação de um composto | |
NO20053809L (no) | Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav | |
CR9182A (es) | Derivado de quinolina, su uso, preparacion y medicamento que lo contiene | |
BR0307444A (pt) | Derivados piridino amiudo como inibidores de moniamina oxidase (mao-b) | |
BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
NO20073760L (no) | Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 9A ANUIDADE. |